Synucleinopathy

Summary

Synucleinopathy (MONDO:0000510) is a disease and 15 clinical trials. Top therapeutic interventions include donanemab, idebenone, and rasagiline. A subtype of neurodegenerative disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	synucleinopathy
Mondo ID	MONDO:0000510
MeSH	D000080874
DOID	DOID:0050890
UMLS	C5191670
MedGen	1682194
GARD	0022781
Is cancer (heuristic)	no

Disease family

This is a subtype of neurodegenerative disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › synucleinopathy

Related subtypes (21): eyelid degenerative disorder, senile degeneration of brain, olivopontocerebellar atrophy, neuroaxonal dystrophy, demyelinating disease, choroidal sclerosis, tauopathy, secondary Parkinson disease, infantile bilateral striatal necrosis, Marchiafava-Bignami disease, superficial siderosis, primary progressive apraxia of speech, human prion disease, primary progressive freezing gait, primary progressive aphasia, motor neuron disorder, brachial amyotrophic diplegia, cerebellar degeneration, inherited neurodegenerative disorder, cerebral degeneration, hypertrophic olivary degeneration

Subtypes (2): Lewy body dementia, multiple system atrophy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE2	3
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05611372	PHASE2/PHASE3	WITHDRAWN	Efficacy and Safety of Rasagiline in Prodromal Parkinson’s Disease
NCT04534023	PHASE2	ACTIVE_NOT_RECRUITING	A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies
NCT06460038	PHASE2	RECRUITING	Tenapanor in Synucleinopathy-Related Constipation
NCT07589595	PHASE2	NOT_YET_RECRUITING	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT06827821	EARLY_PHASE1	NOT_YET_RECRUITING	Application of 18F-CP6A PET Imaging in Synucleinopathies
NCT06193252	Not specified	RECRUITING	Slow-SPEED-NL: Slowing Parkinson’s Early Through Exercise Dosage-Netherlands
NCT06534177	Not specified	NOT_YET_RECRUITING	Digital Diagnostics and Intervention Services for Parkinson’s Disease
NCT06596746	Not specified	RECRUITING	Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
NCT06993142	Not specified	NOT_YET_RECRUITING	Slow-SPEED: Slowing Parkinson’s Early Through Exercise Dosage
NCT07187843	Not specified	RECRUITING	Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD
NCT07324330	Not specified	RECRUITING	Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
NCT07480187	Not specified	ACTIVE_NOT_RECRUITING	Toward Molecular Profiling of Parkinson’s Disease in Easily Accessible Biological Matrices
NCT07533799	Not specified	RECRUITING	The Swedish BioFINDER Sleep Study
NCT05452655	Not specified	UNKNOWN	Intensive Multidisciplinary Rehabilitation and Biomarkers in Parkinson’s Disease
NCT05486806	Not specified	UNKNOWN	Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DONANEMAB	4	1
IDEBENONE	4	1
RASAGILINE	4	1
TENAPANOR	4	1